Table 4.
Dual lateral flow test (LFT) results by brand and days from baseline (study entry or first positive test) for individuals who tested positive
| Day from baseline test-positivity | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Dual LFT results | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
| Concordant |
117 (90.0%) |
129 (93.5%) |
128 (94.8%) |
113 (92.6%) |
114 (91.9%) |
104 (86.0%) |
90 (81.8%) |
83 (87.4%) |
69 (82.1%) |
47 (81.0%) |
| Both positive |
114 (87.7%) |
122 (88.4%) |
123 (91.1%) |
103 (84.4%) |
94 (75.8%) |
73 (60.3%) |
52 (47.3%) |
37 (38.9%) |
20 (23.8%) |
5 (8.6%) |
| Both negative |
3 (2.3%) |
7 (5.1%) |
5 (3.7%) |
10 (8.2%) |
20 (16.1%) |
31 (25.6%) |
38 (34.5%) |
46 (48.4%) |
49 (58.3%) |
42 (72.4%) |
| Discordant |
13 (10.0%) |
9 (6.5%) |
7 (5.2%) |
9 (7.4%) |
10 (8.1%) |
17 (14.0%) |
20 (18.2%) |
12 (12.6%) |
15 (17.9%) |
11 (19.0%) |
| Orient Gene positive |
5 (3.8%) |
3 (2.2%) |
7 (5.2%) |
6 (4.9%) |
5 (4.0%) |
12 (9.9%) |
13 (11.8%) |
8 (8.4%) |
11 (13.1%) |
8 (13.8%) |
| Innova positive |
8 (6.2%) |
6 (4.3%) |
0 (0.0%) |
3 (2.5%) |
5 (4.0%) |
5 (4.1%) |
7 (6.4%) |
4 (4.2%) |
4 (4.8%) |
3 (5.2%) |
| Total | 130 | 138 | 135 | 122 | 124 | 121 | 110 | 95 | 84 | 58 |
Table includes only those participants who tested PCR or LFT positive at study entry or became LFT test-positive throughout the study and counts dual test results they reported on any day. Any LFT pair with any equivocal result was excluded, along with any dual tests prior to the first recorded positive test for each participant